Quality of care in patients with chronic kidney disease is determined by hospital-specific factors

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3647-3654

  Van Zuilen, Arjan D ^a   Blankestijn, Peter J ^a   Van Buren, Marjolijn ^b   Ten Dam, Marc A G J ^c   Kaasjager, Karin A H ^d   Ligtenberg, Gerry ^e   Sijpkens, Yvo W J ^f   Sluiter, Henk E ^g   Van De Ven, Peter J G ^h   Vervoort, Gerald ⁱ   Vleming, Louis Jean ^b   Bots, Michiel L ^a   Wetzels, Jack F M ⁱ  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e Dutch Health Care Insurance Board ^*  (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g DEVENTER HOSPITAL   (Netherlands)

^h Maasstad Hospital Rotterdam   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular risk; Chronic kidney disease; Hospital performance; Prevention; Quality of care

Indexed keywords

ADULT; AIR QUALITY STANDARD; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FACTORIAL ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HOSPITAL CARE; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NURSE PRACTITIONER; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SCORING SYSTEM; AGED; CHRONIC DISEASE; HOSPITAL; KIDNEY DISEASE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FEMALE; HOSPITALS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; QUALITY OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 79952197302     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq184     Document Type: Article

References (29)

1. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003 Apr; 41: I-IV, S1-S91
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002 Feb; 39: S1-S266
3. KDOQI, National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006 May; 47: S11-S145
4. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 May; 43: S1-S290
5. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572 (Pubitemid 37430158)
6. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute, 2002
7. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd B. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001; 37: 484-489 (Pubitemid 32195286)
8. De Nicola L, Minutolo R, Chiodini P et al. Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int 2006; 69: 538-545 (Pubitemid 43164447)
9. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572
10. Jha AK, Li Z, Orav EJ, Epstein AM. Care in U.S. hospitals-The Hospital Quality Alliance program. N Engl J Med 2005; 353: 265-274 (Pubitemid 41058326)
11. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369 (Pubitemid 37430168)
12. van Zuilen AD, Wetzels JF, Blankestijn PJ et al. Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. J Nephrol 2005; 18: 30-34 (Pubitemid 40723750)
13. van Zuilen AD, van der Tweel I, Blankestijn PJ et al. Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]. Trials 2006; 7: 8
14. Wendel-Vos GCW, Schuit AJ, Saris WHM, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess healthenhancing physical activity. J Clin Epidemiol 2003; 56: 1163-1169 (Pubitemid 37532802)
15. Statistics Netherlands. Key Figures of Postal Code Areas 2004. Heerlen: Statistics Netherlands, 2006
16. Levey AS, Greene T, Kusek JW, Beck GL. MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828
17. Harrell FEJr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387 (Pubitemid 26072233)
18. Twisk JWR. Applied Longitudinal Data Analysis for Epidemiology-A practical guide. Cambridge: Cambridge University Press, 2006
19. Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European Countries, Canada, and the United States. Hypertension 2004; 43: 10-17 (Pubitemid 38031904)
20. Pyorala K, Lehto S, De Bacquer D et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004; 47: 1257-1265 (Pubitemid 39093321)
21. Jha AK, Varosy PD, Kanaya AM et al. Differences in medical care and disease outcomes among black and white women with heart disease. Circulation 2003; 108: 1089-1094 (Pubitemid 37071519)
22. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey. Atherosclerosis 2008; 197: 710-717 (Pubitemid 351417868)
23. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
24. van Oort FV, van Lenthe FJ, Mackenbach JP. Material, psychosocial, and behavioural factors in the explanation of educational inequalities in mortality in The Netherlands. J Epidemiol Community Health 2005; 59: 214-220 (Pubitemid 40293112)
25. Wanner C, Krane V, Marz Wet al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 (Pubitemid 41058323)
26. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
27. Tonelli M, Isles C, Curhan GC et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110: 1557-1563 (Pubitemid 39297976)
28. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053 (Pubitemid 38579764)
29. The ESRD Incidence Study Group. Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrol Dial Transplant 2006; 21: 2178-2183